LIVN — LivaNova PLC

Summary of LivaNova PLC Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $361 million, up 9.5% year-over-year on a constant currency and organic basis.
• Full Year Revenue: $1.36 billion, reflecting double-digit growth.
• Adjusted Gross Margin: 68%, consistent with 2024.
• Adjusted Operating Income: $64 million (18% margin), up from $56 million (17% margin) in 2024.
• Adjusted Diluted EPS: $0.86, compared to $0.81 in 2024.
• Cash Position: $636 million, up from $429 million at the end of 2024.
• Total Debt: Reduced to $377 million from $628 million in 2024.
• Adjusted Free Cash Flow: $53 million in Q4, $183 million for the full year, up from $163 million in 2024.

2. Strategic Updates and Business Highlights

• Core Business Growth: Continued strong performance in cardiopulmonary and epilepsy segments, with double-digit EPS growth for five consecutive years.
• Cardiopulmonary Segment: Q4 revenue of $207 million (10% growth), driven by heart-lung machine (HLM) placements and consumables. Full-year revenue grew 13%.
• Epilepsy Segment: Q4 revenue increased 9%, with strong growth in Europe and Rest of World (combined 17%). Full-year revenue grew 6%.
• Innovation Focus: Investments in obstructive sleep apnea (OSA) and digital health platforms, including a new cloud-based clinician portal and Bluetooth-enabled devices.
• Leadership Strengthening: Appointment of Lucille Blaise as Global Head of Commercialization for OSA.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Expected between 6% and 7%, consistent with long-term targets set at the Investor Day.
• Cardiopulmonary Revenue Growth: Forecasted at 7% to 8%, driven by Essence upgrades and market share gains.
• Epilepsy Revenue Growth: Projected at 5.5% to 6.5%, supported by improved reimbursement rates and clinical evidence from CORE VNS study.
• Adjusted EPS Guidance: Expected in the range of $4.15 to $4.25, representing approximately 8% growth at midpoint.

4. Bad News, Challenges, or Points of Concern

• Supply Chain Constraints: Ongoing third-party supply constraints may impact oxygenator output and pricing dynamics.
• Moderation in Pricing: Assumptions include a moderation in price premiums for Essence compared to 2025.
• Reimbursement Risks: Uncertainty surrounding reimbursement for OSA and difficult-to-treat depression, particularly with CMS decisions pending.
• Market Penetration Barriers: Despite improvements, the procedure penetration for epilepsy remains low, with historical barriers still impacting growth.

5. Notable Q&A Insights

• Shift in Tender Activity: Some HLM tenders shifted from Q4 2025 to Q1 2026, but this was not material and is expected to be fully recaptured.
• Epilepsy Growth Drivers: Increased reimbursement rates and positive clinical data are expected to drive growth, though the impact may take time to materialize.
• Medicaid Reimbursement: Medicaid reimbursement is expected to align with Medicare over time, but adjustments will vary by state.
• Commercial Focus: The company is prioritizing reopening accounts that had closed and focusing on value-based pricing discussions.

Overall, LivaNova PLC reported strong financial results for 2025, with a positive outlook for 2026 driven by strategic initiatives and innovation, despite facing some challenges related to supply chain and reimbursement dynamics.